REPLIMUNE GROUP INC
NASDAQ: REPL (Replimune Group, Inc.)
Kemas kini terakhir: 14 jam lalu14.05
-0.76 (-5.13%)
| Penutupan Terdahulu | 14.81 |
| Buka | 14.55 |
| Jumlah Dagangan | 4,249,617 |
| Purata Dagangan (3B) | 5,829,351 |
| Modal Pasaran | 1,323,785,856 |
| Harga / Buku (P/B) | 13.28 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2026 |
| EPS Cair (TTM) | -3.07 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 18.32% |
| Nisbah Semasa (MRQ) | 7.95 |
| Aliran Tunai Operasi (OCF TTM) | -192.25 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -110.31 M |
| Pulangan Atas Aset (ROA TTM) | -31.26% |
| Pulangan Atas Ekuiti (ROE TTM) | -62.58% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Replimune Group, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | -0.38 |
|
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.51% |
| % Dimiliki oleh Institusi | 107.50% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Ridgeback Capital Investments L.P. | 30 Jun 2026 | 7,310,656 |
| Boxer Capital Management, Llc | 30 Jun 2026 | 3,983,000 |
| Fcpm Iii Services B.V. | 30 Jun 2026 | 2,808,368 |
| Erste Asset Management Gmbh | 30 Jun 2026 | 2,120,000 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| HILL EMILY LUISA | - | 13.67 | -11,448 | -156,494 |
| PATEL SUSHIL | - | 13.67 | -39,341 | -537,791 |
| SCHWENDENMAN ANDREW | - | 13.67 | -7,632 | -104,329 |
| XYNOS KONSTANTINOS | - | 13.67 | -11,447 | -156,480 |
| Jumlah Keseluruhan Kuantiti Bersih | -69,868 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -955,096 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 13.67 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| SCHWENDENMAN ANDREW | Pegawai | 10 Aug 2026 | Jual (-) | 7,632 | 13.67 | 104,329 |
| XYNOS KONSTANTINOS | Pegawai | 10 Aug 2026 | Jual (-) | 11,447 | 13.67 | 156,480 |
| HILL EMILY LUISA | Pegawai | 10 Aug 2026 | Jual (-) | 11,448 | 13.67 | 156,494 |
| PATEL SUSHIL | Pegawai | 10 Aug 2026 | Jual (-) | 39,341 | 13.67 | 537,791 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 17 Jun 2026 | CNBC | UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency |
| 29 May 2026 | CNBC | Replimune to resubmit twice-rejected drug for approval after FDA shakeup |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |